首页> 外文期刊>Cancer control : >Trends in direct oral anticoagulant (DOAC) use: health benefits and patient preference
【24h】

Trends in direct oral anticoagulant (DOAC) use: health benefits and patient preference

机译:直接口服抗凝剂(DOAC)的使用趋势:健康益处和患者偏爱

获取原文
           

摘要

In 2012, the Dutch Health Council published a report addressing barriers for an early and broad introduction of direct oral anticoagulants (DOACs). The report raised concerns about the lack of an antidote, adherence, lack of monitoring in the case of overdose and the increased budget impact at DOAC introduction. In the past decade, international studies have shown that DOACs can provide healthcare benefits for a large number of patients. This has led to an increase in the prescription of DOACs, as they are an effective and user-friendly alternative to vitamin K antagonists (VKAs). Unlike VKAs, DOACs do not need monitoring of the international normalized ratio due to more predictable pharmacokinetics. However, the number of prescriptions of DOACs in the Netherlands is still lagging, compared to other European countries. This article highlights the potential health gains in the Netherlands if the use of DOACs were to increase, based on current international experience.
机译:2012年,荷兰卫生委员会发布了一份报告,探讨了早期和广泛采用直接口服抗凝剂(DOAC)的障碍。该报告引起了人们对缺乏解毒剂,依从性,过量服用缺乏监控以及DOAC引入预算影响增加的担忧。在过去的十年中,国际研究表明,DOAC可以为大量患者提供医疗保健益处。由于它们是维生素K拮抗剂(VKA)的有效且用户友好的替代品,因此导致DOAC处方的增加。与VKA不同,DOAC由于需要更可预测的药代动力学,因此无需监控国际标准化比率。但是,与其他欧洲国家相比,荷兰的DOAC处方数量仍然滞后。根据当前的国际经验,本文重点介绍了如果增加使用DOAC的话在荷兰可能带来的健康收益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号